The FDA has approved IV ocrelizumab for treatment of relapsing-remitting MS in children and adolescents aged 10 years and ...

The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...

Shares in Sanofi were sliding today after a double dose of bad news for its oral BTK inhibitor tolebrutinib, in development as a therapy for multiple sclerosis (MS). Along with what looks set to be ...

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 millionRaises ...

NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE)-- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without ...

Illustration of human lymphocytes. (Ruslanas Baranauskas/Science Photo Library) Defeating obesity is rarely easy. For many ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

People who live with obesity are "tagging" a memory of being overweight on a key part of the immune system—leaving people ...

With five novel oral therapies in late-stage development, there could soon be a wide range of treatment options for relapsing–remitting multiple sclerosis, but better biomarkers are needed to more ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Fingolimod Capsules ...

Recommendation based on the HERCULES phase 3 study which demonstrated that brain-penetrant Cenrifki (tolebrutinib) significantly delayed the onset of disability progression in non-relapsing SPMS Paris ...